AZN
April 29, 2025 - AI Summary
Overvalued by 44.8% based on the discounted cash flow analysis.
Market cap | $209.68 Billion |
---|---|
Enterprise Value | $235.40 Billion |
Dividend Yield | $1.54 (1.42188169426426%) |
Earnings per Share | $1.14 |
Beta | 0.18 |
Outstanding Shares | 6,200,000,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 27.17 |
---|---|
PEG | 72.95 |
Price to Sales | 8.45 |
Price to Book Ratio | 11.26 |
Enterprise Value to Revenue | 4.28 |
Enterprise Value to EBIT | 21.45 |
Enterprise Value to Net Income | 29 |
Total Debt to Enterprise | 0.13 |
Debt to Equity | 0.75 |
No data
No data
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...